Letrozole Dose Increments in PCOS Patients Resistant to Letrozole - Trial NCT06403488
Access comprehensive clinical trial information for NCT06403488 through Pure Global AI's free database. This Phase 3 trial is sponsored by Beni-Suef University and is currently Completed. The study focuses on Polycystic Ovary Syndrome. Target enrollment is 102 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beni-Suef University
Timeline & Enrollment
Phase 3
Oct 01, 2023
Jan 30, 2024
Primary Outcome
ovulation rate,endometrial thickness
Summary
Objectives: To study the effect of Letrozole dose increments on ovulation rate and
 endometrial thickness as a primary outcomes in patients with polycystic ovary syndrome who
 previously resistant to letrazole conventional dose, and chemical and clinical pregnancy
 considered as secondary outcomes.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06403488
Non-Device Trial